Published in Histopathology on January 01, 2010
Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol (2015) 0.87
The significance of markers in the diagnosis of endometrial cancer. Prz Menopauzalny (2016) 0.75
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Ambra1 regulates autophagy and development of the nervous system. Nature (2007) 6.94
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 3.60
Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A (2005) 3.22
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
Perivascular epithelioid cell tumor (PEComa) of the uterine cervix associated with intraabdominal "PEComatosis": A clinicopathological study with comparative genomic hybridization analysis. World J Surg Oncol (2004) 2.33
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res (2010) 2.15
Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med (2005) 2.06
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol (2006) 1.87
Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene (2003) 1.65
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol (2012) 1.55
A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm (2011) 1.43
Women's choice between sentinel lymph node biopsy and axillary clearance. ANZ J Surg (2002) 1.42
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol (2005) 1.40
Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification. J Clin Pathol (2013) 1.37
MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol (2010) 1.29
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer (2006) 1.27
Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol (2003) 1.22
Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res (2004) 1.20
Effects of a nursing intervention on quality of life outcomes in post-surgical women with gynecological cancers. Psychooncology (2009) 1.19
Functional analysis of seven genes encoding eight translation initiation factor 4E (eIF4E) isoforms in Drosophila. Mech Dev (2004) 1.17
Identification of binding sites of EVI1 in mammalian cells. J Biol Chem (2005) 1.16
Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol (2011) 1.15
ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol (2007) 1.10
Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol (2007) 1.09
Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol (2002) 1.08
Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J Soc Gynecol Investig (2004) 1.08
Epithelioid trophoblastic tumor: clinicopathological features with an emphasis on uterine cervical involvement. Mod Pathol (2006) 1.08
Isolated noncompaction of the ventricular myocardium: clinical and molecular aspects of a rare cardiomyopathy. Lab Invest (2002) 1.07
Synovial sarcoma of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases. Am J Surg Pathol (2008) 1.07
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol (2013) 1.05
Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. Int J Cancer (2011) 1.03
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther (2010) 1.03
Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett (2002) 1.03
Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol (2004) 1.02
STAT3-mediated signaling in the determination of rod photoreceptor cell fate in mouse retina. Invest Ophthalmol Vis Sci (2004) 1.02
Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecol Oncol (2006) 1.01
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. Int J Clin Exp Pathol (2013) 1.01
Osteoclast-independent bone resorption by fibroblast-like cells. Arthritis Res Ther (2003) 1.01
BRAF mutation testing in clinical practice. Expert Rev Mol Diagn (2012) 1.00
Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J Biol Chem (2011) 0.99
Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells. Am J Reprod Immunol (2010) 0.99
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer (2009) 0.99
Cesarean scar ectopic pregnancy: case series and review of the literature. Am J Perinatol (2009) 0.99
Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis. Thyroid (2013) 0.99
Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment. Cell Cycle (2012) 0.99
Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells. Biol Reprod (2002) 0.98
Multiple angiomyolipomata of the liver: a case report. Mod Pathol (2002) 0.97
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med (2013) 0.95
MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med (2006) 0.93
BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol (2012) 0.93
HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. J Clin Pathol (2010) 0.93
Quality of life among women after surgery for ovarian cancer. Palliat Support Care (2008) 0.91
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. J Soc Gynecol Investig (2006) 0.91
MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol (2011) 0.90
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Med (2014) 0.90
A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev (2002) 0.90
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Purinergic signaling regulates cell proliferation of olfactory epithelium progenitors. Stem Cells (2009) 0.90
Hormonal therapy for aggressive angiomyxoma: a case report and proposed management algorithm. J Low Genit Tract Dis (2014) 0.89
Clinical problem-solving. Venting the spleen. N Engl J Med (2013) 0.89
Atypical angiomyolipoma of kidney in a patient with tuberous sclerosis: a case report with p53 gene mutation analysis. Arch Pathol Lab Med (2005) 0.88
Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience. Int J Gynecol Cancer (2014) 0.88
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol (2013) 0.88
Lack of genetic association between exaggerated placental site reaction and placental site trophoblastic tumor. Int J Gynecol Pathol (2008) 0.88
BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta Cytol (2011) 0.87
Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid (2011) 0.87
Comparison of Affirm VPIII and Papanicolaou tests in the detection of infectious vaginitis. Am J Clin Pathol (2011) 0.87
Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma. Am J Clin Pathol (2007) 0.87
Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol (2005) 0.87
Healthcare utilization in women after abdominal surgery for ovarian cancer. Nurs Res (2010) 0.86
High grade cervical intraepithelial neoplasia and viral load of high-risk human papillomavirus: significant correlations in patients of 22 years old or younger. Int J Clin Exp Pathol (2008) 0.86
Glial heterotopia of the uterine cervix: DNA genotyping confirmation of its fetal origin. Int J Gynecol Pathol (2010) 0.86
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res (2011) 0.86
High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci (2012) 0.86
Genotypic analysis of hydatidiform mole: an accurate and practical method of diagnosis. Am J Surg Pathol (2008) 0.85
Precise DNA genotyping diagnosis of hydatidiform mole. Obstet Gynecol (2010) 0.85
Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol (2013) 0.85
Regulation of Fas ligand expression by estrogen in normal ovary. J Soc Gynecol Investig (2002) 0.84
Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma. Eur J Cancer (2004) 0.84
Partial hydatidiform mole: histologic parameters in correlation with DNA genotyping. Int J Gynecol Pathol (2013) 0.84
MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol (2009) 0.84
Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology (2012) 0.83